Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert opinion about laser and intense pulsed light (IPL)-induced leukoderma or vitiligo: a cross-sectional survey study.
Post NF, Van Broekhoven NX, Lommerts A, Bae JM, Bekkenk MW, de Castro CCS, Eleftheriadou V, Esmat S, Ezzedine K, van Geel N, Hamzavi I, Leone G, Pandya AG, Passeron T, Rodrigues MA, Seneschal J, Th'ng S, Wolkerstorfer A. Post NF, et al. Among authors: seneschal j. Arch Dermatol Res. 2023 Oct;315(8):2289-2294. doi: 10.1007/s00403-023-02611-8. Epub 2023 Mar 25. Arch Dermatol Res. 2023. PMID: 36964767 Free PMC article.
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Rosmarin D, et al. Among authors: seneschal j. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. N Engl J Med. 2022. PMID: 36260792
Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, Tobin DJ, Randhawa S, Winkler A, Telliez JB, Martin D, Lejeune A. Passeron T, et al. Among authors: seneschal j. Front Immunol. 2023 Nov 6;14:1243556. doi: 10.3389/fimmu.2023.1243556. eCollection 2023. Front Immunol. 2023. PMID: 38022501 Free PMC article. Review.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey.
Augustin M, Costanzo A, Pink A, Seneschal J, Schuster C, Mert C, Guerreiro M, Tietz N, Grond S, De Bruin-Weller M. Augustin M, et al. Among authors: seneschal j. Acta Derm Venereol. 2022 Dec 7;102:adv00830. doi: 10.2340/actadv.v102.3932. Acta Derm Venereol. 2022. PMID: 36479885 Free PMC article.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: seneschal j. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.
Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T; French Atopic Dermatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group. Beyrouti A, et al. Among authors: seneschal j. J Allergy Clin Immunol Pract. 2024 Dec 12:S2213-2198(24)01241-8. doi: 10.1016/j.jaip.2024.12.001. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 39672377
Effect of Therapeutic Patient Education in Adults with Atopic Dermatitis: Analysis of Efficacy and Treatment Needs.
Fargeas M, Fauvernier M, Tauber M, Seneschal J, Verdu V, Bourrel Bouttaz M, Hacard F, Darrigade AS, Nosbaum A; Eczema Foundation; French Group on Therapeutic Education in Dermatology (GET). Fargeas M, et al. Among authors: seneschal j. Acta Derm Venereol. 2024 Dec 12;104:adv41184. doi: 10.2340/actadv.v104.41184. Acta Derm Venereol. 2024. PMID: 39670437 Free PMC article.
Comorbidity burden on mortality in patients with systemic sclerosis.
Fauthoux T, Brisou D, Lazaro E, Seneschal J, Constans J, Skopinski S, Duffau P, Blanchard E, Contin-Bordes C, Barnetche T, Truchetet ME. Fauthoux T, et al. Among authors: seneschal j. RMD Open. 2024 Oct 18;10(4):e004637. doi: 10.1136/rmdopen-2024-004637. RMD Open. 2024. PMID: 39424406 Free PMC article.
Sexuality impairment in patients with atopic dermatitis.
Misery L, Seneschal J, Corgibet F, Halioua B, Sampogna F, Merhand S, Skayem C, Hayoun YB, Taieb C, Staumont-Sallé D, Ezzedine K, Richard MA. Misery L, et al. Among authors: seneschal j. Clin Exp Dermatol. 2024 Sep 4:llae360. doi: 10.1093/ced/llae360. Online ahead of print. Clin Exp Dermatol. 2024. PMID: 39229930 No abstract available.
219 results